Is Shifting to a Progestin Worthwhile When Estrogen-Progestins Are Inefficacious for Endometriosis-Associated Pain? by P. Vercellini et al.
Vercellini et al., 1 
IS SHIFTING TO A PROGESTIN WORTHWHILE WHEN ESTROGEN-PROGESTINS  1 
ARE INEFFICACIOUS FOR ENDOMETRIOSIS-ASSOCIATED PAIN? 2 
 3 
Running Head: From estrogen-progestins to progestins for inefficacy on endometriosis-associated 4 
pain 5 
 6 
Paolo Vercellini, M.D.a,b        ORCID 0000-0003-4195-0996     paolo.vercellini@unimi.it 7 
Federica Ottolini, M.D.a          federica_ottolini@libero.it 8 
Maria Pina Frattaruolo, M.D.b      ORCID 0000-0001-7288-0113     mp.frattaruolo@gmail.com 9 
Laura Buggio, M.D.a,b        ORCID 0000-0002-1199-1888     buggiolaura@gmail.com 10 
Anna Roberto, Biol.Sci.D.c        ORCID 0000-0002-6756-1297     anna.roberto@marionegri.it 11 
Edgardo Somigliana, M.D.a,b        ORCID 0000-0002-0223-0032     dadosomigliana@yahoo.it 12 
 13 
From the a Department of Clinical Sciences and Community Health, Università degli Studi di 14 
Milano and bFondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda 15 
Ospedale Maggiore Policlinico, Via Commenda, 12 - 20122 Milan, Italy; cDepartment of Public 16 
Health, IRCCS Mario Negri Institute for Pharmacological Research, Via La Masa 19, 20156 Milan, 17 
Italy. 18 
 19 
Correspondence: 20 
Prof. Paolo Vercellini 21 
Istituto Ostetrico e Ginecologico “Luigi Mangiagalli” 22 
Via Commenda 12 – 20122 Milano, Italy 23 
Tel. +3902.55032917; fax: +3902.55032818; electronic address: paolo.vercellini@unimi.it 24 
25 
Vercellini et al., 2 
ABSTRACT 26 
The purpose of this study was to assess the proportion of patients satisfied with their treatment after 27 
a change from a low-dose oral contraceptive (OC) to norethisterone acetate (NETA) because of 28 
inefficacy of OC on pain symptoms.  29 
To this end, prospective, self-controlled study was conducted on 153 women using OC as a 30 
treatment for endometriosis, and with persistence of one or more moderate or severe pain 31 
symptoms. At baseline and during 12 months after a shift from OC to oral NETA, 2.5 mg/day, 32 
pelvic pain was measured by means of a 0 to 10-point numerical rating scale and a 33 
multidimensional categorical rating scale. Variations in health-related quality of life, psychological 34 
status, and sexual function were also evaluated with validated scales. At the end of the study period 35 
participants indicated the degree of satisfaction with their treatment according to a 5-degree scale 36 
from very satisfied to very dissatisfied. 37 
A total of 28 women dropped out of the study, the main reason being intolerable side effects 38 
(n=15). At 12-month assessment, 70% of participants were very satisfied or satisfied with NETA 39 
treatment (intention-to-treat analysis). Statistically significant improvements were observed in 40 
health-related quality of life, psychological status, and sexual function. At per-protocol analysis, 41 
almost half of the patients (58/125) reported sub-optimal drug tolerability. However, complains 42 
were not severe enough to cause dissatisfaction, drug discontinuation, or request for surgery. 43 
These encouraging results could be used to counsel women with symptomatic endometriosis not 44 
responding to OC, and inform their decisions on modifications of disease management.  45 
 46 
KEYWORDS: endometriosis; pelvic pain; medical treatment; combined oral contraceptives; 47 
progestins.48 
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INTRODUCTION 49 
Estrogen-progestins and progestins are currently considered as first-line treatments for symptomatic 50 
endometriosis in women not seeking pregnancy and without absolute surgical indications, such as 51 
adnexal masses of doubtful ultrasonographic appearance or large endometriomas, ureteral stenosis 52 
with hydronephrosis, and bowel stenosis causing persistent subocclusive symptoms.1-5  53 
 In women with endometriosis-associated pelvic pain, some authors suggest starting 54 
treatment with low-dose, combined, monophasic, oral contraceptive pills (OCs), and shifting to 55 
progestin monotherapy in case OCs are inefficacious or not tolerated.6 This stepwise pharmacologic 56 
approach is based on metabolic, psychological, and practical considerations. Low-dose OCs have 57 
been proven safe when used in women without definite contraindications,7-9 whereas the most 58 
popular progestins used for endometriosis treatment may alter the serum lipid profile10,11 or affect 59 
bone mineralization.12-15 As OCs are generally not perceived as medications for an illness, their use 60 
may limit the psychological burden of disease labelling.16,17 Finally, when used continuously, OCs 61 
allow easy management of erratic bleeding through tailored cycling, whereas this modality may 62 
result less successful with progestin monotherapy. 63 
 However, this approach has been recently criticized as, based on published biological and 64 
clinical evidence, OCs might reveal less effective than progestins in controlling endometriosis, 65 
relieving associated pain symptoms, and preventing lesion progression.18 Indeed, OCs have been 66 
indicated even as a risk factor for the development of deep, infiltrating lesions.19 The issue here 67 
would be the supra-physiologic concentrations of estrogens contained in OCs, as 5 mg of ethinyl-68 
estradiol (EE) are equivalent to around 1 mg of micronized estradiol or 0.625 mg of conjugated 69 
equine estrogen.18 Thus, even low-dose OCs containing only 15-20 mg of EE would create a hyper-70 
estrogenic environment resulting in suboptimal lesion and symptom control despite adequate 71 
combined progestin doses.18   72 
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 Given this background, we deemed of interest to investigate which degree of pain symptom 73 
improvement and satisfaction with treatment could be obtained by shifting to a progestin 74 
monotherapy in women in whom low-dose OCs use did not relieve pain.  75 
 76 
MATERIALS AND METHODS 77 
The manuscript was prepared according to the Strengthening the Reporting of Observational studies 78 
in Epidemiology guidelines for reporting observational studies.20 The main objective of the present 79 
study was to assess the proportion of patients satisfied with their treatment after a change from a 80 
low-dose, monophasic OC to norethisterone acetate (NETA) because of inefficacy of OC on pain 81 
symptoms (persistence of one or more moderate or severe pain symptoms, including dysmenorrhea, 82 
deep dyspareunia, non-menstrual pain, and dyschezia). Secondary objective was the evaluation of 83 
variations in pain symptoms, health-related quality of life, psychological status, and sexual function 84 
associated with the shift from OC to NETA. 85 
 The investigation was performed in an academic department, and the competent Institutional 86 
Review Board approved the study (Comitato Etico Fondazione IRCCS Ca' Granda - Ospedale 87 
Maggiore Policlinico, determination #786/2013). Patients signed an informed consent form before 88 
enrolment. Women who denied their consensus were excluded. 89 
 90 
Design 91 
A prospective, self-controlled study design was adopted with the objective of assessing within-92 
person comparisons before and after the shift from OC to NETA. With this study design each 93 
participant acts as her own control, in order to avoid the inherent biases caused by differences 94 
between patients.21 In fact, the objective of the study was to assess variations in efficacy when 95 
shifting to NETA not in a general population of patients taking OC, but specifically in those 96 
patients who were dissatisfied because of inefficacy of OC and that would have otherwise 97 
discontinued medical therapy.  98 
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Study participants 99 
 We considered 18- to 40-year old women, not seeking conception, with a surgical diagnosis 100 
of endometriosis in the previous 24 months or with a current non-surgical diagnosis of 101 
endometriosis,22 and using an OC for pelvic pain, but unwilling to continue or modify (change of 102 
OC type or modality of assumption) the current treatment because of inefficacy on symptoms and 103 
overall dissatisfaction with OCs.  104 
 Non-surgical diagnoses were based on ultrasonographic criteria in patients with ovarian 105 
endometriomas;23,24 on visual inspection of the posterior fornix and biopsy of vaginal lesions in 106 
those with rectovaginal endometriosis;10,25 on ultrasonographic criteria,26 cystoscopic findings, and 107 
biopsy of vesical lesions in those with bladder detrusor endometriosis; on physical signs at recto-108 
vaginal examination and ultrasonographic criteria27,28 in those with deep lesions infiltrating the 109 
Douglas pouch and parametria; and on ultrasonographic criteria23,28 double contrast barium enema 110 
and rectosigmoidoscopy or colonoscopy findings in those with full-thickness bowel lesions. 111 
Magnetic resonance imaging was performed in selected circumstances.  112 
 Women were referred or self-referred to our tertiary-care outpatient clinic for the treatment 113 
of endometriosis. Patients were excluded in case of use of drugs that interfere with ovarian steroid 114 
metabolism; allergy to components of the study medication or to NSAIDs; abnormal findings at 115 
breast examination and mammary ultrasound scan; an abnormal cervical smear; a diagnosis of 116 
concomitant disorders that may cause pelvic pain independently of endometriosis presence (e.g., 117 
pelvic inflammatory disease or pelvic varices or genital malformations at previous surgery; known 118 
urologic and orthopedic diseases); psychiatric disturbances; and history of drug or alcohol abuse.  119 
Participants were recruited during the period August 2014 – July 2015.  120 
 Women were informed that OCs are considered by some authors as the first-line treatment 121 
for endometriosis-associated pelvic pain, but that further medical therapy steps are available in case 122 
of inefficacy. They were also informed that medical therapies for endometriosis are usually 123 
effective in reducing various types of pain in more than two thirds of patients.29-31 However, drugs 124 
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induce only temporary relief, are not expected to be definitively curative, and may cause several 125 
side effects (listed, with percentages derived from previous studies conducted in our centre). 126 
Finally, when hormonal treatments are to be continued for long periods, estrogen-progestins and 127 
progestins appear to be among the compounds that most favourably balance benefits, harm and 128 
costs.17,32-34 129 
 In case of pain persistence, it was explained that the estrogen included in OCs on one hand 130 
may prevent potentially detrimental effects of hypo-estrogenizing treatments (e.g., decrease in bone 131 
mineral density and unfavourable modifications in serum lipid pattern), but on the other hand may 132 
limit the therapeutic efficacy on endometriotic implants that, being estrogen-sensitive, may retain 133 
part of their metabolic activity. Women were informed that other drugs for symptomatic 134 
endometriosis were available but, owing to severe untoward effects and/or high costs, generally 135 
they were not suggested for prolonged treatment periods. Finally, patients were also informed that 136 
laparoscopic surgery was a reasonable alternative in case they declined switching from a OC to a 137 
progestin, but that pain and lesion recurrence was about 10% a year without long-term 138 
postoperative medical therapy.35,36 139 
 140 
Treatments 141 
The OCs used in our centre were monophasic formulations containing ethinyl-estradiol 0.015 mg 142 
and gestodene 60 mg or, in case of spotting, ethinyl-estradiol 0.02 mg and desogestrel 150 mg. In 143 
smokers and in those with a BMI ≥ 30, a combination of ethinyl-estradiol 0.02 mg and 144 
levonorgestrel 100 mg was prescribed.  145 
 Norethisterone acetate, a 19-nortestosterone derivative progestin, has been repeatedly 146 
evaluated in women with endometriosis,37-43 and has been routinely used in our referral centre for 147 
several years.6,10,25,44 Norethisterone acetate is approved by the FDA and the Italian Ministry of 148 
Health for the treatment of endometriosis and is reimbursed by the Italian National Health System. 149 
Norethisterone acetate was prescribed at the dose of 2.5 mg once a day, per os. The progestin was 150 
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started after 4-7 days since OC discontinuation, depending on the type of OC previously used, and 151 
it was continued without preplanned time limits. However, for the purpose of the present study, 152 
only the first 12 months of use have been evaluated. In case of prolonged spotting (≥ 7 days) or 153 
breakthrough bleeding, the patients were advised to discontinue treatment for one week. When 154 
needed, naproxen sodium was the standard non-steroidal anti-inflammatory drug prescribed (one 155 
550-mg tablet twice a day unless contraindicated).  156 
 157 
Measurements 158 
All patients assisted in our centre systematically undergo clinical and ultrasonographic evaluation 159 
every six months. On these occasions, women are routinely asked to complete five questionnaires, 160 
two on pain (a numerical rating scale, NRS; and a multi-dimensional categorical rating scale, 161 
MCRS), one on quality of life (the Short Form-12 questionnaire, SF-12), one on psychological 162 
status (the Hospital Anxiety and Depression scale, HADS), and one on sexual functioning (the 163 
Female Sexual Function Index, FSFI). Women are also asked to indicate drug tolerability using a 164 
NRS and to rate the degree of satisfaction with their treatment. 165 
 The above scales and questionnaires have been described previously in detail.6,10,25,44,45 The 166 
presence and severity of dysmenorrhea, deep dyspareunia, non-menstrual pelvic pain, and 167 
dyschezia were assessed using an 11-point NRS, with 0 indicating absence of pain and 10 pain as 168 
bad as it could be. Patients were also asked to grade the severity of the above symptoms using a 0- 169 
to 3-point MCRS modified from that devised by Biberoglu and Behrman.46 Irregular bleeding 170 
during treatment was defined as spotting (scanty bleeding requiring ≤ 1 pad or tampon per day) or 171 
breakthrough bleeding (light or moderate bleeding requiring ≥ 2 pads or tampons per day). Pain 172 
during spotting or breakthrough bleeding was considered as dysmenorrhea.  173 
 The SF-12 health survey, developed from the original SF-36 questionnaire,47,48 is a well 174 
know, validated self-administered 12-item instrument. It measures health dimensions covering 175 
functional status, well-being, and overall health. Information from the 12 items is used to construct 176 
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physical (PCS-12) and mental (MCS-12) component summary measures,49,50 with higher scores 177 
indicating better health perception. 178 
 The HADS questionnaire is a self-assessment mood scale specifically designed for use in 179 
non-psychiatric hospital outpatients to determine states of anxiety and depression. It comprises 14 180 
questions, 7 for the anxiety subscale and 7 for the depression subscale. Lower scores indicate better 181 
psychological status.51 182 
 The FSFI questionnaire is a 19-item, multidimensional, self-report instrument for evaluating 183 
the main categories of female sexual dysfunction and sexual satisfaction.52-54 The transformed 184 
maximum score for each domain is 6, and the maximum (best) transformed full-scale score is 36, 185 
with a minimum full-scale score of 2.0.  186 
 Occurrence of side effects associated with medical treatments is actively investigated in our 187 
endometriosis outpatient clinic, and the overall tolerability of hormonal therapies is measured using 188 
a 0- to10-point NRS, with 0 indicating absolutely intolerable untoward effects and 10 absence of 189 
adverse effects. Scores are then categorized, with 9-10 indicating that a drug is very well tolerated; 190 
7-8, well tolerated; 5-6, moderately tolerated; 3-4, poorly tolerated; 0-2, not tolerated.6 191 
 Patients rated the degree of satisfaction after the modification of their treatment according to 192 
a five-category scale (very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, very 193 
dissatisfied) by answering the following question: “Taking into consideration the variations 194 
occurred in pain symptoms, overall physical and psychological well-being, health-related quality of 195 
life, and sexual functioning, how would you define the level of satisfaction with your current 196 
treatment?” For this study, only women that were dissatisfied or very dissatisfied with their OC 197 
treatment because of inefficacy on pain (one or more persistent pain symptom > 5 points as 198 
measured by the NRS) were considered. In order to limit the potential effect of confounding, 199 
satisfaction with treatment, the main study outcome, was dichotomized into “satisfied” (very 200 
satisfied plus satisfied) and “dissatisfied” (neither satisfied nor dissatisfied plus dissatisfied plus 201 
very dissatisfied). 202 
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Data management 203 
The focus of the investigation was not a head-to-head comparison between OC and NETA but, 204 
instead, quantification of the proportion of women who were satisfied with NETA treatment 12 205 
months after OC discontinuation because of inefficacy. No study is available to define the potential 206 
benefits of progestins over OCs in this clinical condition. Therefore, a pre-planned power 207 
calculation was not performed, and we decided to include all the eligible patients evaluated in a 1-208 
year period. 209 
 Data were archived using Excel 2003 (Microsoft Corporation, Redmond, Washington, 210 
U.S.A.) and exported in SPSS 18.0 (SPSS, Inc, Chicago, IL, U.S.A.) or SAS software 9.4 (SF-12 211 
data; SAS Institute Inc., Cary, NC, U.S.A.) for statistical analysis. Estimate of patient satisfaction 212 
rate was performed according to the intention-to-treat principle, considering as dissatisfied all 213 
patients who dropped out of the study for any reason except conception seeking, thus including 214 
request for surgery and lost to follow-up. Variations in pelvic pain symptoms, health-related quality 215 
of life, psychological status, sexual functioning, and drug tolerability between baseline and 12-216 
month values were evaluated by using the paired Student t test for normally distributed data, the 217 
non-parametric Wilcoxon matched pairs test for non-normally distributed data, the McNemar test 218 
for categorical variables, and the Fisher Exact test in case of cells without numerical data. 219 
Determinants of satisfaction with treatment were investigated with unpaired tests (Student t test for 220 
normally distributed continuous variables, Wilcoxon test for non-normally distributed continuous 221 
variables, and the chi-squared test for categorical variables). All statistical tests were two-sided. A P 222 
value < 5% was considered statistically significant. When appropriate, 95% confidence intervals 223 
(CIs) of proportions were calculated by applying a binomial distribution model. 224 
 225 
RESULTS 226 
A total of 153 women evaluated during the recruitment period were enrolled in the study (Figure 1). 227 
The baseline demographic and clinical characteristics of the patients are shown in Table 1. Two 228 
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thirds of women previously underwent surgery for endometriosis, and all had stage III-IV disease 229 
according to the revised American Society for Reproductive Medicine (ASRM) classification55, 230 
except one patient who had stage II endometriosis. A total of 116 (76%) patients had deep 231 
endometriotic lesions, and 91 (60%) had ovarian endometriomas. The median [interquartile range, 232 
IQR] duration of previous OC use was 9 [5–24] months. One hundred-two women (67%) were 233 
using OC cyclically and 51 (33%) continuously. Sixty-four subjects (42%) were dissatisfied with 234 
OC use also because of side effects in addition to inefficacy on pain symptoms. However, 235 
inefficacy was the main reason for dissatisfaction also in these 64 subjects independently of 236 
intolerance. The most frequent side effects were headache (15%) and spotting/breakthrough 237 
bleeding (15%).  238 
 A total of 125 women completed the preplanned 12-month study period, whereas 28 (18%) 239 
dropped out of the study before the 6-month follow-up evaluation (n = 2), or between the 6- and the 240 
12-month assessment (n = 26; Figure 1). Overall, 15 women referred one or more intolerable side 241 
effects with NETA as the reason for abandoning the study (headache n = 7; erratic bleeding, n = 6; 242 
weight increase, n =4; abdominal bloating, n = 4; acne, n = 2; mood nausea, decreased libido, 243 
vaginal dryness, breast tenderness, depressed mood, n = 1 each). 244 
 A significant reduction in symptoms’ severity as measured by both the NRS and the MCRS 245 
scales was observed when comparing baseline and 12-month measurements (Table 2). Median 246 
[IQR] dysmenorrhea NRS scores decreased from 8 [6-9] to 0 [0-0] after 1 year of NETA treatment. 247 
According to the MCRS, menstrual pain was moderate or severe in 94/125 (75%) women at 248 
baseline evaluation, but in only one at 12-month follow-up assessment. The variations in deep 249 
dyspareunia, non-menstrual pain, and dyschezia followed a similar pattern. In particular, median 250 
[IQR] deep dyspareunia NRS scores, evaluated in the 114 women who were sexually active both at 251 
baseline and 12-month follow-up, decreased from 7 [1-8] to 0[0-5]. According to the MCRS 54/114 252 
(47%) women suffered from moderate-to severe pain at intercourse at baseline, compared with 253 
15/114 (13%) after 1 year of NETA treatment (Table 2).  254 
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 Only the physical component of the SF-12 improved at the end of the study period, whereas 255 
no substantial variation was observed in the mental component of the health-related quality of life 256 
questionnaire (Table 2). However, when the psychological status was evaluated by means of 257 
HADS, significant reductions were observed in the scores of both anxiety and depression 258 
questionnaire components. According to the FSFI, a statistically significant amelioration of sexual 259 
functioning was observed in the 114 sexually active women at baseline and end of follow-up (Table 260 
2).  261 
At final per-protocol analysis, almost half of the patients (58/125) reported sub-optimal drug 262 
tolerability. However, complains were not severe enough to cause dissatisfaction, drug 263 
discontinuation, or request for surgery. Side effects referred at baseline and at 12-month evaluation 264 
are shown in Table 3. After switching from OC to NETA, the prevalence of headache, spotting, and 265 
nausea decreased significantly. The mean ± SD tolerability score as assessed by the NRS increased 266 
from 5.4 ± 2.6 during OC use to 6.9 ± 2.5 after 12 months of NETA treatment. Overall, 34% 267 
(42/125) women scored their tolerability as good or very good (NRS ≥ 7), compared with 54% 268 
(67/125) at 12-month assessment.  269 
 When evaluating the degree of satisfaction with NETA treatment at the end of the study 270 
period, four women who discontinued the drug between 6- and 12-month follow-up visits because 271 
of pregnancy desire were excluded, as variation in satisfaction with treatment during time is 272 
unpredictable. Eventually, 105/149 patients (70%; 95% C.I., 63% to 77%) were satisfied or very 273 
satisfied with NETA treatment, whereas 44/149 (30%; 95% C.I., 23% to 37%) were neither 274 
satisfied nor dissatisfied, dissatisfied, or very dissatisfied. The baseline demographic and clinical 275 
characteristics of the 105 patients satisfied with NETA treatment and those of the 44 dissatisfied 276 
ones were substantially similar. A statistically significant difference was observed only for non-277 
menstrual pain, which was more severe at both the NRS and the MCRS in the group of dissatisfied 278 
patients (Supplemental Tables 1 and 2).  279 
Vercellini et al., 12 
 The impact of the two potentially relevant variables, i.e., the modality of OC use (cyclic 280 
versus continuous) before switching to NETA, and type of endometriotic lesions (deep lesions 281 
versus ovarian endometriomas) was investigated. The proportion of satisfied patients was 24/33 282 
(73%; 95% C.I., 57% to 86%) in women with deep lesions and previous continuous OC use; 54/80 283 
(68%; 95% C.I., 57% to 77%) in those with deep lesions and previous cyclic OC use; 11/17 (65%; 284 
95% C.I., 42% to 84%) in those with ovarian endometriosis and previous continuous OC use; and 285 
16/19 (84%; 95% C.I., 64% to 96%) in those with ovarian endometriosis and previous cyclic OC 286 
use.  287 
 288 
DISCUSSION 289 
According to the results of the present study, slightly more than two thirds of women with 290 
endometriosis experiencing pelvic pain symptoms despite OC use were satisfied one year after 291 
shifting to NETA treatment. The satisfaction rate at the end of the study period was not significantly 292 
influenced neither by the modality of previous OC use, nor by the type of endometriotic lesion 293 
present, thus supporting the consistency of the general results. However, with one exception, all the 294 
patients who underwent previous surgery had ASRM stage III-IV endometriosis, and all those who 295 
were recruited based on non-surgical criteria had ovarian endometriomas or deep infiltrating 296 
lesions. Therefore, our results may not be generalizable to women with early stage disease. 297 
 Pain symptoms' scores decreased during NETA treatment. The reduction of dysmenorrhea 298 
scores was expected as most participants experienced progestin-induced amenorrhea. The effect of 299 
NETA on deep dyspareunia is worthier of note and confirms our previous findings on patients with 300 
severe pain at intercourse.25,44 Only a tiny minority of women referred moderate or severe non-301 
menstrual pain and dyschezia at the end of the study period. Overall, except some women with deep 302 
dyspareunia as their main complaint, the shift from an OC to NETA was of substantial benefit for 303 
patients who were still moderately or severely symptomatic despite OC use. This seems important 304 
because, in similar circumstances, this “third way” can be chosen as an alternative to stepping-up by 305 
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using drugs with less favorable therapeutic profiles (e.g., GnRH agonists and danazol) or 306 
undertaking surgery. Moreover, this finding supports the view that, in some women, the estrogen 307 
component of OCs may not allow sufficient inhibition of ectopic endometrium metabolism, thus 308 
occasionally limiting the efficacy of these medications in relieving endometriosis-associated pelvic 309 
pain symptoms.18  310 
 Also the increased tolerability of NETA compared with that of OC may have influenced the 311 
likelihood of being satisfied with the treatment received. Indeed, as medical therapy for 312 
endometriosis is not definitively curative, the issue of tolerability, in addition to that of safety and 313 
efficacy, is crucial, because long periods of treatment should be foreseen. The reduction in the 314 
frequency of nausea and headache after shifting from OC to NETA was expected, as these side 315 
effects are typically associated with estrogens.56 The decrease in the frequency of spotting confirms 316 
the good control of NETA on erratic uterine bleeding.6,10,39,40,43  317 
 Nevertheless, slightly less than half of the patients who completed the study period (per-318 
protocol analysis) referred that NETA was moderately, poorly, or not tolerable, although not to the 319 
point of causing dissatisfaction, drug discontinuation, or request for surgery. Moreover, the majority 320 
of participants who dropped out of the study did so because of side effects. Tolerance is a 321 
determinant of patient compliance and adherence to drugs, and should receive more focus in future 322 
trials on medical treatment for endometriosis. In fact, according to major international guidelines, 323 
the efficacy of various hormonal compounds on pain is similar, whereas side effects vary.1-4 324 
  The physical component of the SF-12 questionnaire improved significantly during NETA 325 
treatment, whereas the mental component did not. This last finding is at odds with the ameliorations 326 
observed in both the anxiety and depression dimensions of the HADS scale. We do not have an 327 
explanation for this apparent discrepancy, and random fluctuation of data, or incapacity of the SF-328 
12 scale to capture differences in this particular domain, cannot be excluded. 329 
 Also sexual function, as measured by the FSFI, improved significantly. However, as 330 
repeatedly observed,6,44,57 the mean score remained well below the cut-off for a physiologic 331 
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condition. We have previously interpreted this finding as a demonstration that impacting on a single 332 
dimension, i.e., pain at intercourse, of a multifactorial experience such as sexual life, may not 333 
completely restore a complex physiological function. Moreover, NETA reduced libido and 334 
lubrication in some women. However, also it may not be excluded that the FSFI cut-off may be 335 
inappropriate for a population of endometriosis patients. Therefore, observing the overall trend in 336 
FSFI scores' variation during treatment might be more opportune than focusing on the achievement 337 
of the exact and potentially arbitrary cut-off score of 26.55.  338 
 The self-controlled design may appear as a limitation of our study. However, this model was 339 
chosen because our aim was not to compare OC and NETA in a parallel-group, randomized, 340 
controlled trial (RCT), but rather to evaluate sequentially the effect of NETA used as a second-line 341 
treatment modality specifically in a selected group of non-responders to OC. In this setting, 342 
recruited patients acted as their own control, thus limiting the effect of confounding inherent to 343 
other designs. In fact, relevant characteristics that can influence study outcomes may differ between 344 
patients.21 The use of multivariable analyses should account for these differences in observational 345 
studies, but residual confounding may not be excluded. Moreover, the intention-to-treat analysis 346 
adopted to investigate patient satisfaction included all drop-outs except women who discontinued 347 
treatment to seek a conception. Thus, overoptimistic results should have been avoided. Moreover, 348 
even if a placebo effect cannot be excluded, it is presumably limited given that this is a population 349 
of women who already experienced a treatment failure and were thus presumably less prone to a 350 
placebo effect. Noteworthy, given the pragmatic approach of this study, i.e., reflecting real world 351 
clinical management, the existence of a placebo component in the determinisms of the observed 352 
findings would not invalidate the general conclusions.  353 
 However, the "regression toward the mean" phenomenon could theoretically explain at least 354 
partly the results observed in a self-controlled study. In fact, extreme values are likely unduly 355 
influenced by random variation and, when re-measured, they tend to be closer to the mean of the 356 
original population from which the study subjects were drawn.58,59 Therefore, when the patients’ 357 
Vercellini et al., 15 
conditions are worse than average and they are enrolled in a self-controlled study of a new therapy 358 
because standard regimens seem to have lost efficacy, some general amelioration may occur that 359 
has nothing to do with improved treatment.58 Despite this, the impact of regression toward the mean 360 
should have been limited in our study, as we considered patients complaining of chronic and fairly 361 
stable pain symptoms that were measured on more than one occasion during the pre-enrollment 362 
phase.58 363 
 Observational studies are not suited to assess efficacy, that is whether a new, experimental 364 
treatment can work. For this purpose, the explanatory RCT is the standard investigational modality. 365 
However, observational studies can be used to assess whether interventions that have already been 366 
proven to work under ideal circumstances, work also in real life.60,61 Therefore, observational 367 
studies are useful to evaluate effectiveness and efficiency and, in case of medical treatment for 368 
endometriosis, to define the prospective role of the available medications in different clinical 369 
conditions.61 370 
 A pre-planned power analysis was not performed, but the sample size of our study was 371 
larger than that theoretically required to detect as statistically significant the observed difference 372 
between baseline and 12-month follow-up values in most outcome measures. The relatively high 373 
dropout rate (28/153, 18%) was not surprising, given that the study population was generally at 374 
unfavourable prognosis considering the persistence of moderate to severe pain symptoms despite 375 
OC use, and the related patient dissatisfaction status. In this regard, it may be hypothesized that the 376 
use of dienogest instead of NETA could have led to greater efficacy57 and/or better tolerability,6 and 377 
thus higher degree of satisfaction with treatment. However, we have selected NETA because many 378 
patients in our centre cannot afford the much higher cost of dienogest.6 In fact, our general policy is 379 
to prescribe dienogest only in case of intolerance to NETA.   380 
 In our opinion, the results of the present study should not lead to systematic prescription of 381 
progestins as the first-line treatment for endometriosis, but should rather be used when counselling 382 
non-respondents to OCs. Progestin treatment for years may raise some safety concerns.11,14-16,62,63 383 
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Therefore, these drugs should be chosen to step-up when OC are not effective on pain (or not 384 
tolerated or contraindicated), or in presence of severely infiltrating lesions, when a more profound 385 
inhibition of ectopic endometrium metabolism is desirable. More in general, we believe that the 386 
current approach to management of endometriosis, characterized by selection, among available 387 
alternatives, of the purportedly most efficacious intervention on the basis of head-to-head 388 
comparisons, should be substituted by a stepwise approach that takes into consideration not only 389 
absolute efficacy, but also safety, tolerability, and costs, in order to define an overall therapeutic 390 
profile. Medications with the most favorable therapeutic profile should be chosen first, stepping-up, 391 
in non-responders only, to medications that, although with a less favourable overall therapeutic 392 
profile, are more effective on pain.16  393 
 We are convinced that women suffering from endometriosis badly need answers to 394 
questions that matter to them. These questions are those that physicians face in their everyday 395 
practice. Performance of RCTs is nowadays problematic for independent investigators, owing to 396 
unreasonable increase in administrative bureaucracy and often unaffordable insurance costs.61 On 397 
the other hand, industry supported, explanatory RCTs have almost exclusively registration purposes 398 
and may not provide those answers that are important to patients.34,64,65 Indeed, we are not aware of 399 
RCTs investigating medical or surgical alternatives specifically for symptomatic women not 400 
responding to OC use. With this study we have tried to provide a pragmatic description of what 401 
could be obtained by simply shifting from an OC to an inexpensive progestin. In this frequently 402 
encountered clinical situation, two out of three patients benefitted from this change of medication, 403 
and were satisfied with the new treatment after one year of use. Precisely because our investigation 404 
was not conducted under ideal experimental conditions, our data should be generalizable and could 405 
be used to counsel non-responders to OC, in order to help informing their decisions on how to 406 
modify the management of their disease.  407 
408 
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Table 1. Distribution of baseline demographic and clinical characteristics of women who shifted to norethisterone 
acetate for inefficacy of low-dose oral contraceptive (n = 153). 
Characteristic   Enrolled patients 
  (n = 153) 
Age (years) 33.4 ± 5.4 
BMI (Kg/m2) 21.4 ± 3.7 
Smoking 31 (20.3%) 
Previous deliveries 37 (24%) 
Previous interventions for endometriosisa 
  None 51 (33%) 
 1 79 (52%) 
 2 18 (12%) 
 ≥ 3   5 (3%) 
Endometriotic lesion typeb 
  Deep infiltrating endometriosis 116 (76%) 
 Ovarian endometriomas   91 (60%) 
Estroprogestin use 
  Duration [months] 9 [5-24] 
Continuous use 51 (33%) 
Cyclic use 102 (67%) 
 
Data is reported as mean ± SD, or number (percentage), or median [interquartile range]. 
BMI = body mass index. 
a A total of 101/102 of the women who underwent previous surgery had stage III-IV endometriosis according to the 
revised American Society for Reproductive Medicine classification55. 
bThe sum does not add to the total as some women had both lesion types. 
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Table 2. Per-protocol analysisa of pain symptoms, health-related quality of life, psychological status, and sexual 
functioning scores variation between baseline and 12-month evaluation in patients (n = 125) shifting from low-dose 
oral contraceptive to norethisterone acetate for inefficacy on pain.  
Symptoms / Questionnaires Baseline 12 months P 
Dysmenorrhea 
   
NRS 8 [6-9] 0 [0-0] <0.001 
MCRS ≥ 2 94 (75%) 1 (1%) <0.001 
Deep dyspareunia b 
   NRS 7 [1-8] 0 [0-5] <0.001 
MCRS ≥ 2 54 (47%) 15 (13%) <0.001 
Non-menstrual pelvic pain 
   NRS 5 [0-7] 0 [0-2] <0.001 
MCRS ≥ 2 48 (38%) 4 (3%) <0.001 
Dyschezia 
   NRS 4 [0-7] 0 [0-0] <0.001 
MCRS ≥ 2 52 (42%) 5 (4%) <0.001 
SF-12 
   Physical component 30.7 ± 11.0 53.4 ± 6.7 <0.001 
Mental component 45.0 ± 9.7 46.3 ± 9.9 NS 
 HADS     
Anxiety 12.3 ± 6.6 9.5 ± 6.4 <0.001 
Depression 6.2 ± 3.3 5.0 ± 3.2 0.001 
Total 6.1 ± 3.6 4.5 ± 3.6 <0.001 
FSFI total scoreb 21.4 ± 6.3 24.5 ± 6.4 <0.001 
Data is reported as mean ± SD, or number (percentage), or median [interquartile range]. 
NRS = 0-10-point Numerical rating scale. MCRS = 0-3-point multidimensional categorical rating scale modified from 
that devised by Biberoglu and Behrman46. SF-12 = Short Form-1250. HADS = Hospital Anxiety and Depression 
Scale51. FSFI = Female Sexual Function Index52,53. NS = not significant. 
aWomen who withdrew before 12-month follow-up assessment (n = 28) were excluded. 
bEleven women did not have sexual intercourses either at baseline and/or at 12-month evaluation. 
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Table 3. Per-protocol analysis of frequency of side effects reported at baseline and at 12-month evaluation by 
patients (n = 125) shifting from oral contraceptive to norethisterone acetate. 
Side effectsa Baseline 12 months P 
 
   
Headache 42 (34%) 28 (22%) 0.03 
Spotting 39 (31%) 11 (9%) <0.001 
Breakthrough bleeding 4 (3%) 0 (0%) NS 
Weight gain 32 (26%) 38 (30%) NS 
Nausea 11 (9%) 2 (2%) 0.001 
Decreased libido 35 (28%) 45 (36%) NS 
Vaginal Dryness 37 (30%) 44 (35%) NS 
Bloating or swelling 17 (14%) 13 (10%) NS 
Breast tenderness 6 (5%) 5 (4%) NS 
Acne 1 (1%) 3 (2%) NS 
Alopecia 0 (0%) 3 (2%) NS 
Mood disorders 9 (7%) 17 (14%) NS 
Others 13 (10%) 14 (11%) NS 
aSome women reported more than one side effect.   
Data are number (percentage). 
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Supplemental Table 1. Comparison of the baseline demographic and clinical characteristics of women who were 
satisfied and women who were not satisfied after 12 months of treatment with norethisterone acetate (n = 149). 
Characteristic 
Satisfied Not satisfied 
 P 
  n = 105     n = 44 
Age (years) 33.4 ± 5.5 33.5 ± 5.4 NS 
BMI (Kg/m2) 21.3 ± 3.6 21.4 ± 4.3 NS 
Smoking 20 (69%) 9 (31%) NS 
Previous deliveries 25 (67%) 12 (33%) NS 
Previous interventions for endometriosisa 75 (74%) 26 (26%) NS 
Endometriotic lesion typeb 
    Deep infiltrating endometriosis 78 (69%) 35 (31%) NS 
 Ovarian endometriomas 68 (76%) 21 (24%) NS 
Estroprogestin use 
   Duration [months] 9 [6-14] 10 [4-24] NS 
Continuous use 35 (70%) 15 (30%) NS 
Cyclic use 70 (71%) 29 (29%) 
 Pain symptoms 
   Dysmenorrhea 83 (71%) 33 (29%) NS 
Deep dyspareuniac 57 (70%) 24 (30%) NS 
Non-menstrual pelvic pain 59 (68%) 28 (32%) NS 
Dyschezia 37 (66%) 19 (34%) NS 
Side effects (in addition to pain) 44 (70%) 19 (30%) NS 
Data is reported as mean ± SD, or median [interquartile range], or number (percentage). Row percentages are reported. 
BMI = body mass index. NS = not significant. 
Women who withdrew for seeking pregnancy (n=4) were excluded. 
Women who withdrew before the 12-month follow-up were considered as not satisfied (n=24). 
aA total of 100/101 of the women who underwent previous surgery had stage III-IV endometriosis according to the 
revised American Society for Reproductive Medicine classification55. 
bThe sum does not add to the total as some women had both lesion types. 
cEleven women did not have sexual intercourses either at baseline and/or at 12-month evaluation. 
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Supplemental Table 2. Comparison of baseline clinical assessment of women who were satisfied and women who 
were not satisfied after 12 months of treatment with norethisterone acetate (n = 149).  
Symptoms / Questionnaires Satisfied Not satisfied 
P 
  n = 105 n = 44 
Dysmenorrhea    
NRS 8 [6-9] 7 [5-8] NS 
MCRS ≥ 2 80 (76%) 31 (70%) NS 
Deep dyspareunia a    
NRS 7 [0-8] 8 [4-9] NS 
MCRS ≥ 2 46 (45%) 25 (61%) NS 
Non-menstrual pelvic pain    
NRS 5 [0-7] 7 [5-8] 0.002 
MCRS ≥ 2 37 (35%) 25 (57%) 0.015 
Dyschezia    
NRS 4 [0-7] 6 [0-8] NS 
MCRS ≥ 2 44 (42%) 23 (52%) NS 
SF-12    
Physical component 30.1 ± 10.3 31.3 ± 12.8 NS 
Mental component 45.4 ± 9.6 44.2 ± 9.9 NS 
HADS     
Anxiety 6.0 ± 3.2 6.2 ± 3.3 NS 
Depression 6.0 ± 3.5 6.5 ± 4.0 NS 
Total 12.0 ± 6.4 12.7 ± 7.0 NS 
FSFI total score a 21.5 ± 6.2 21.2 ± 6.4 NS 
Tolerabilityb    
NRS 5.4 ± 2.5 5.9 ± 2.9 NS 
Well tolerated (NRS  7) 35 (33%) 18 (41%) NS 
 
Data is reported as mean ± SD, or median [interquartile range], or number (percentage).  
NRS = 0-10-point Numerical rating scale. MCRS = 0-3-point multidimensional categorical rating scale modified from 
Vercellini et al., 32 
that devised by Biberoglu and Behrman46. SF-12 = Short Form-1250. HADS = Hospital Anxiety and Depression 
Scale51. FSFI = Female Sexual Function Index52,53.  NS = not significant. 
Women who withdrew for seeking pregnancy (n=4) were excluded.   
Women who withdrew before the 12-month evaluation were considered as not satisfied (n=24).  
aRefers to 99 satisfied women and 41 not satisfied women.    
bAssessed using a 0 to 10-point numeric scale and a 5-category scale: very well tolerated, well tolerated, moderately 
tolerated, poorly tolerated, not tolerated. 
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